CTLA-4 gene polymorphism at position +49 A>G in exon 1: A risk factor for cervical cancer in Indian women

Cancer Genetics

Volumn 206, Issue 5, 2013, Pages 154-161

  Gokhale, Priyanka ^a   Kerkar, Shilpa ^a   Tongaonkar, Hemant ^b,c   Salvi, Vinita ^d,e   Mania Pramanik, Jayanti ^a  

^a NATIONAL INSTITUTE FOR RESEARCH IN REPRODUCTIVE HEALTH   (India)

^b TATA MEMORIAL HOSPITAL   (India)

^c P D HINDUJA NATIONAL HOSPITAL   (India)

^d KEM HOSPITAL   (India)

^e Seven Hills Hospital   (India)

Author keywords

Cervical cancer; CTLA 4; HPV; India

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CTLA 4 GENE; EXON; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; INDIAN; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA;

CERVICAL CANCER; CTLA-4; HPV; INDIA;

CASE-CONTROL STUDIES; CTLA-4 ANTIGEN; FEMALE; HAPLOTYPES; HUMANS; INDIA; LOGISTIC MODELS; PAPILLOMAVIRUS INFECTIONS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS;

EID: 84881259346     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2013.04.003     Document Type: Article

References (48)

1. Human Papillomavirus and Related Cancers, WHO/ICO HPV Information Centre, Third Edition, Summary Report Update, September 15, 2010. Accessed on August 27,2012. http://apps.who.int/hpvcentre/statistics/dynamic/ico/country_pdf/IND.pdf.
2. Wu T.C. Immunology of human papillomavirus in relation to cancer. Curr Opin Immunol 1994, 6:746-754.
3. Lenschow D.J., Walunas T.L., Bluestone J.A. CD 28/B7 system of T-cell costimulation. Annu Rev Immunol 1996, 14:233-258.
4. Krummel M.F., Allison J.P. CD28 and CTLA-4 have opposing effects on the response of T-cells to stimulation. JExp Med 1995, 182:459-465.
5. Maker A.V., Phan G.Q., Attia P., et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005, 12:1005-1016.
6. Paterson A.M., Vanguri V.K., Sharpe A.H. SnapShot: B7/CD28 costimulation. Cell 2009, 137:974. 4.e.1.
7. Egen J.G., Kuhns M.S., Allison J.P. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002, 3:611-618.
8. Leach D.R., Krummel M.F., Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996, 271:1734-1736.
9. Hurwitz A.A., Foster B.A., Kwon E.D., et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000, 60:2444-2448.
10. Van Elsas A., Hurwitz A.A., Alison J.P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. JExp Med 1999, 190:355-366.
11. Ueda H., Howson J.M., Esposito L., et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003, 423:506-511.
12. Yee L.J., Perez K.A., Tang J., et al. Association of CTLA-4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection. JInfect Dis 2003, 187:1264-1271.
13. Mohammad Alizadeh A.H., Hajilooi M., Ranjbar M., et al. Cytotoxic T-lymphocyte antigen 4 gene polymorphisms and susceptibility to chronic hepatitis B. World J Gastroenterol 2006, 12:630-635.
14. Sun T., Zhou Y., Yang M., et al. Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer. Cancer Res 2008, 68:7025-7034.
15. Wang L., Li D., Fu Z., et al. Association of CTLA-4 gene polymorphism with sporadic breast cancer in Chinese Han population. BMC Cancer 2007, 7:173-179.
16. Erfani N., Razmkhah M., Talei A.R., et al. Cytotoxic T lymphocyte antigen 4 promoter variants in breast cancer. Cancer Genet Cytogenet 2006, 165:114-120.
17. Hadinia A., Hossieni S.V., Erfani N., et al. CTLA-4 gene promoter and exon 1 polymorphisms in Iranian patients with gastric and colorectal cancers. JGasteroenterol Hepatol 2007, 22:2283-2287.
18. Cozar J.M., Romero J.M., Aptsiauri N., et al. High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. Hum Immunol 2007, 68:698-704.
19. Wong Y.K., Chang K.W., Cheng C.Y., et al. Association of CTLA-4 gene polymorphism with oral squamous cell carcinoma. JOral Pathol Med 2006, 35:51-54.
20. Rahimifar S., Erfani N., Sarraf Z., et al. CTLA-4 gene variations may influence cervical cancer susceptibility. Gynec Oncol 2010, 119:136-139.
21. Hu L., Liu J., Chen X., et al. CTLA-4 gene polymorphism +49 A/G contributes to genetic susceptibility to two infection-related cancers-hepatocellular carcinoma and cervical cancer. Hum Immunol 2010, 71:888-891.
22. Su T.-H., Chang T.-Y., Lee Y.-J., et al. CTLA-4 gene and susceptibility to human papillomavirus-16-associated cervical squamous cell carcinoma in Taiwanese women. Carcinogenesis 2007, 28:1237-1240.
23. Ghaderi A. CTLA-4 gene variants in autoimmunity and cancer: a comparative review. Iran J Immunol 2011, 8:127-149.
24. Pawlak E., Karabon L., Wlodarska-Polinska I., et al. Influence of CTLA-4/CD28/ICOS gene polymorphisms on susceptibility to cervical squamous cell carcinoma and stage differentiation in the polish population. Hum Immunol 2010, 71:195-200.
25. Jiang L., Luo R., Zhang W., et al. Single nucleotide polymorphisms of CTLA-4 gene and their association with human cervical cancer [Chinese]. Zhonghua Xi Xue Chuan Xue Za Zhi 2011, 28:3.
26. Ivansson E.L., Juco-Pecirep I., Gyllensten U.B. Interaction of immunological genes on chromosome 2q33 and IFNG in susceptibility to cervical cancer. Gynecol Oncol 2010, 116:544-548.
27. Li H., Zhou Y.F., Guo H.Y., et al. Association between CTLA-4 gene polymorphism and susceptibility to cervical cancer [Chinese]. Zhonghua Zhong Liu Za Zhi 2011, 33:681-684.
28. Zheng J., Yu X., Jiang L., et al. Association between the Cytotoxic T lymphocyte antigen 4 +49 G>A polymorphism and cancer risk: meta analysis. BMC Cancer 2010, 10:522-532.
29. Zhang Y., Zhang J., Deng Y., et al. Polymorphisms in the cytotoxic T lymphocyte antigen 4 gene and cancer risk. Cancer 2011, 117:4312-4324.
30. Veeramuthumari P., Isabel W., Kannan K. Astudy on the level of T3, T4, TSH and association of A/G polymorphism with CTLA-4 gene in Grave's hyperthyroidism among South Indian population. Ind J Clin Biochem 2011, 26:66-69.
31. Deeba F., Syed R., Quareen J., et al. CTLA-4 A49G gene polymorphism is not associated with vitiligo in South Indian population. Ind J Dermatol 2010, 55:29-32.
32. Lahiri D.K., Nurnberger J.I. Arapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 1991, 19:5444.
33. Ting Y., Manos M.M. Detection and typing of genital human papillomavirus. PCR Protocols 1990, 356-367. Academic Press, San Diego. M.A. Innis, D.H. Gelfand, J.J. Sninsky, T.J. White (Eds.).
34. Kerkar S.C., Latta S., Salvi V., et al. Human papillomavirus infection in asymptomatic population. Sexual Reprod Healthc 2011, 2:7-11.
35. Barrett J.C., Fry B., Maller J., et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
36. Lancaster A., Nelson M.P., Meyer D., et al. PyPop: a software framework for population genomics: analyzing large-scale multi-locus genotype data. Pac Symp Biocomput 2003, 514-525.
37. Dillner J. Primary screening for human papillomavirus infection. Best Prac Res Clin Obstet Gynaecol 2011, 15:743-757.
38. Misra J.S., Srivastava S., Singh U., et al. Risk factors and strategies for control of carcinoma cervix in India: hospital based cytological screening experience of 35 years. Indian J Cancer 2009, 46:155-159.
39. Munoz N., Franceschi S., Bosetti C., et al. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet 2002, 359:1093-1101.
40. Nistico L., Buzzetti R., Pritchard L.E., et al. The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Hum Mol Genet 1996, 5:1075-1080.
41. Chistiakov D.A., Savostanov K.V., Turakulov R.I., et al. Genetic analysis and functional evaluation of the C/T(-318) and A/G(-1661) polymorphisms of the CTLA-4 gene in patientsaffected with Grave's disease. Clin Immunol 2006, 118:233-242.
42. Donnadieu E., Cookson W.O., Jouvin M.H., et al. Allergy-associated polymorphisms of the Fc epsilon RI beta subunit do not impact its two amplification functions. JImmunol 2000, 165:3917-3922.
43. Maurer M., Loserth S., Kolb-Maurer A., et al. Apolymorphism in human cytotoxic T lymphocyte antigen 4 (CTLA4) gene (exon 1 +49) alters T-cell activation. Immunogenetics 2002, 54:1-8.
44. Ohlschlager P., Osen W., Dell K., et al. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. JVirol 2003, 77:4635-4645.
45. Steele J.C., Mann C.H., Rookes S., et al. T-cell responses tohuman papillomavirus type 16 among women with differentgrades of cervical neoplasia. Br J Cancer 2005, 93:248-259.
46. Sun T., Hu Z., Shen H., et al. Genetic polymorphisms in cytotoxic T-lymphocyte antigen 4 and cancer: the dialectical nature of the subtle human immune dysregulation. Cancer Res 2009, 69:6011-6014.
47. Alegre M.L., Frauwirth K.A., Thompson C.B. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 2001, 1:220-228.
48. Wang X.B., Zhao X., Giscombe R., et al. ACTLA-4 gene polymorphism at position -318 in the promoter region affects theexpression of the protein. Genes Immun 2002, 3:233-234.